Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2510924 + Carboplatin/Etoposide in Extensive-Stage SCLC
NCT01439568Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2011
- Primary completion
- Jan 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LY2510924 in small cell lung cancer (SCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival up to 59 Months. Started Sep 2011; status: completed.
02
Drugs
LY2510924
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01439568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01439568.